Delivery Order SPE2DB22D7058-SPE2DB25FSXM3
- Not listed
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,568,244 vials of 110 mg Artesunate. The award has a ceiling value of $33,451.08 and a period of performance extending through May 15, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999.00 with the...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of ARTESUNAT 110MG 2S pharmaceutical products. The $19,920.75 contract has a performance period through March 6, 2024. Amerisourcebergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies, most notably the Department...
- This delivery order, awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corporation, has a potential value of one hundred five thousand six hundred eighty-five dollars and seventy-six cents ($105,685.76) to supply four hundred fifty-six thousand two hundred forty-eight thousand nine hundred ninety-four (4562489499) units of artesunate, a medication used to treat malaria, in one hundred ten (110) milligram vials. The contract has a firm fixed price and period of performance through...
- This delivery order, awarded August 12, 2025, by the Defense Logistics Agency (DLA) Medical Supply Chain, provides $4,129.20 in firm fixed price funding to AmerisourceBergen Drug Corp for the supply of Coartem 20-120mg in 24-unit quantities. The contract, which is not set-aside and was competitively awarded, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,790.18 by the Defense Logistics Agency's Medical Supply Chain on July 30, 2025, with completion due by July 31, 2025. This firm fixed-price, non-set-aside contract calls for the delivery of Atovaquone-Proguanil 250-100 mg unit dose packages in quantities of 24, a combination antimalarial medication used primarily for malaria prophylaxis and treatment in military and veteran...
- The U.S. Defense Medical Supply Chain awarded a $5,859 delivery order to AmerisourceBergen Drug Corp for Malarone 250/100 (100 tablets), a pharmaceutical antimalarial medication. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 16, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency. The work will be performed at the contractor's corporate office in...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,089.39 firm fixed-price delivery order is for the medical supply MALARONE 250/100 100S. The contract has a completion date of June 3, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,162.57 contract is for the delivery of COARTEM TABLETS 24S, a medical supply, with a period of performance ending on July 2, 2025. The contract is not set aside and represents open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $41,480.40 to AmerisourceBergen Drug Corp on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award carries no set-aside designation...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $87,321.50 to AmerisourceBergen Drug Corp on August 25, 2025, with completion expected by August 26, 2025. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The delivery order will be performed at AmerisourceBergen's...
- SPE2DB22D7058Indefinite Delivery Contract
- SPE2DB22D7058-SPE2DB25FSXM3Delivery Order
The Defense Logistics Agency (DLA) awarded a $20,786.31 delivery order to AmerisourceBergen Drug Corp for the supply of Artesunate 110 mg vials, with a completion date of September 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The contract includes no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete in open federal procurement for pharmaceutical supplies. Artesunate is a WHO-approved antimalarial medication critical for military medical readiness and deployed personnel healthcare support. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a primary pharmaceutical distributor for the federal government's military and defense healthcare systems. The company's comprehensive federal contract portfolio demonstrates extensive experience delivering brand-name and generic pharmaceuticals, vaccines, specialty medications, and medical supplies across multiple therapeutic areas to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. This delivery order reflects the company's ongoing role as a critical vendor within DLA's pharmaceutical supply chain, supporting the military's global medical logistics operations and healthcare mission requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.8k | 8/29/25 |